STREAMEX CORP. (STEX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 19.16M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -98.65M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $19.16M | $-98.65M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | $-103.86M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $31.00K | (m) | $869.00K | $-71.09M | $1.60M | (m) | (m) | -44.43× | Reported |
| 2025-09-30 | $127.00K | (m) | (m) | $-30.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $277.00K | (m) | (m) | $-27.48M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $600.00K | (m) | (m) | $-12.41M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $832.00K | $40.00K | (m) | $-12.86M | (m) | 2080.00% | (m) | (m) | (m) |
| 2024-09-30 | $1.91M | $39.00K | (m) | $-17.85M | (m) | 4902.56% | (m) | (m) | (m) |
| 2024-06-30 | $2.90M | $40.00K | (m) | $-18.95M | (m) | 7252.50% | (m) | (m) | (m) |
| 2024-06-05 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $4.27M | $27.00K | (m) | $-24.56M | (m) | 15807.41% | (m) | (m) | (m) |
| 2023-12-31 | $5.09M | $18.00K | (m) | $-28.51M | (m) | 28288.89% | (m) | (m) | (m) |
| 2023-09-30 | $5.04M | $141.00K | (m) | $-29.34M | (m) | 3571.63% | (m) | (m) | (m) |
| 2023-06-30 | $5.62M | $275.00K | (m) | $-31.78M | (m) | 2045.09% | (m) | (m) | (m) |
| 2023-03-31 | $5.27M | $283.00K | (m) | $-26.59M | (m) | 1860.78% | (m) | (m) | (m) |
| 2022-12-31 | $5.82M | $286.00K | (m) | $-27.27M | (m) | 2035.31% | (m) | (m) | (m) |
| 2022-09-30 | $6.05M | $159.00K | (m) | $-29.27M | (m) | 3808.18% | (m) | (m) | (m) |
| 2022-06-30 | $5.64M | $132.00K | (m) | $-30.58M | (m) | 4270.45% | (m) | (m) | (m) |
| 2022-03-31 | $5.95M | $331.00K | (m) | $-32.92M | (m) | 1798.49% | (m) | (m) | (m) |
| 2021-12-31 | $5.60M | $441.00K | $0.00 | $-33.41M | (m) | 1270.29% | 0.00% | (m) | (m) |
| 2021-09-30 | $6.83M | (m) | (m) | $-35.34M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $10.42M | (m) | (m) | $-40.64M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $14.47M | (m) | (m) | $-54.94M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $18.14M | (m) | $1.30M | $-59.18M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $20.34M | (m) | $16.48M | $-63.49M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $17.08M | (m) | $16.48M | $-55.89M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $13.18M | (m) | $16.92M | $-41.53M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $9.74M | (m) | $15.18M | $-34.60M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $2.76M | (m) | $9.95M | $-10.45M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $1.86M | (m) | $8.38M | $-8.10M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $1.49M | (m) | $8.88M | $-5.88M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.37M | (m) | $6.60M | $-17.26M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $4.01M | (m) | $7.95M | $-16.63M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $4.39M | (m) | $7.61M | $-15.39M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $4.28M | (m) | $4.58M | $-12.64M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $4.76M | (m) | $4.75M | $-12.91M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $4.32M | (m) | $1.69M | $-9.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $3.75M | (m) | $1.94M | $-9.23M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $3.62M | (m) | $5.44M | $-11.75M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $2.65M | (m) | $6.00M | $-11.16M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $2.23M | (m) | $6.51M | $-11.49M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $2.03M | (m) | $7.77M | $-12.41M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $1.31M | (m) | $7.45M | $-11.31M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $1.24M | (m) | $7.97M | $-12.04M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $1.11M | (m) | $8.69M | $-12.56M | (m) | (m) | (m) | (m) | (m) |
| 2015-08-17 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $956.53K | (m) | $10.53M | $-14.03M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $727.92K | (m) | $7.03M | $-10.19M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $548.00K | (m) | $5.74M | $-7.87M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $992.21K | (m) | $3.31M | $-6.24M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B |